盐酸氨溴索结构式
|
常用名 | 盐酸氨溴索 | 英文名 | Ambroxol HCl |
|---|---|---|---|---|
| CAS号 | 23828-92-4 | 分子量 | 414.564 | |
| 密度 | N/A | 沸点 | 468.6ºC at 760 mmHg | |
| 分子式 | C13H19Br2ClN2O | 熔点 | 235 - 240ºC | |
| MSDS | 中文版 美版 | 闪点 | 237.2ºC |
盐酸氨溴索用途Ambroxol hydrochloride (NA-872 hydrochloride) 是前药溴己辛的活性代谢产物,具有强效祛痰作用。Ambroxol hydrochloride 是一种葡糖脑苷脂酶 (GCase) 伴侣,可增加葡糖脑苷脂酶的活性。Ambroxol hydrochloride 可诱导肺自噬,并有用于帕金森氏病和神经性戈谢病研究的潜力。 |
| 中文名 | 盐酸氨溴索 |
|---|---|
| 英文名 | Ambroxol hydrochloride |
| 中文别名 | 2-氨基-3,5-二溴-N-(反式-4-羟基环己基)苄胺 |
| 英文别名 | 更多 |
| 描述 | Ambroxol hydrochloride (NA-872 hydrochloride) 是前药溴己辛的活性代谢产物,具有强效祛痰作用。Ambroxol hydrochloride 是一种葡糖脑苷脂酶 (GCase) 伴侣,可增加葡糖脑苷脂酶的活性。Ambroxol hydrochloride 可诱导肺自噬,并有用于帕金森氏病和神经性戈谢病研究的潜力。 |
|---|---|
| 相关类别 | |
| 体内研究 | 在转基因小鼠脑组织中,连续表达糖甙酶871-2天,转基因小鼠脑组织糖酶活性增加。 |
| 参考文献 |
| 沸点 | 468.6ºC at 760 mmHg |
|---|---|
| 熔点 | 235 - 240ºC |
| 分子式 | C13H19Br2ClN2O |
| 分子量 | 414.564 |
| 闪点 | 237.2ºC |
| 精确质量 | 411.955261 |
| PSA | 58.28000 |
| LogP | 4.96100 |
| 外观性状 | 白色至淡黄色结晶粉末 |
| 储存条件 | 库房通风低温干燥 |
| 个人防护装备 | dust mask type N95 (US);Eyeshields;Gloves |
|---|---|
| 危害码 (欧洲) | Xn: Harmful; |
| 风险声明 (欧洲) | R22 |
| 安全声明 (欧洲) | 36 |
| 危险品运输编码 | NONH for all modes of transport |
| WGK德国 | 3 |
| RTECS号 | GV8423000 |
| 海关编码 | 2922199090 |
| 海关编码 | 2922199090 |
|---|---|
| 中文概述 | 2922199090. 其他氨基醇及其醚,酯和它们的盐(但含一种以上含氧基的除外). 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:30.0% |
| 申报要素 | 品名, 成分含量, 用途, 乙醇胺及其盐应报明色度, 乙醇胺及其盐应报明包装 |
| Summary | 2922199090. other amino-alcohols, other than those containing more than one kind of oxygen function, their ethers and esters; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
|
Gastro retention using polymer cocoons.
Artif. Cells. Nanomed. Biotechnol. 43(1) , 26-32, (2015) A gastro-retentive capsule has been prepared which is retained in the stomach for a period of 24h, providing a vehicle for the controlled delivery to the upper intestines. These "gastro cocoons" can r... |
|
|
Enzyme enhancers for the treatment of Fabry and Pompe disease.
Mol. Ther. 23(3) , 456-64, (2015) Lysosomal storage disorders (LSD) are a group of heterogeneous diseases caused by compromised enzyme function leading to multiple organ failure. Therapeutic approaches involve enzyme replacement (ERT)... |
|
|
Jauch, R., et al.
Arzneimittelforschung 13 , 474, (1963)
|
| Antobron |
| trans-4-[(2-Amino-3,5-dibromobenzyl)amino]cyclohexanol hydrochloride |
| Ambron |
| DURAMUCAL |
| trans-4-[(2-Amino-3,5-dibromobenzyl)amino]cyclohexanol hydrochloride (1:1) |
| mucolear |
| trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride |
| trans-4-[(2-Amino-3,5-dibromobenzyl)amino]cyclohexanol chlorhydrate |
| MFCD00078932 |
| FLUIXOL |
| cis-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride |
| Cyclohexanol, 4-[[(2-amino-3,5-dibromophenyl)methyl]amino]-, trans-, hydrochloride (1:1) |
| ABRAMEN |
| trans-4-(((2-Amino-3,5-dibromophenyl)methyl)amino)cyclohexan-1-ol hydrochloride |
| 2-Amino-3,5-dibromo-N-(trans-4-hydroxycyclohexyl)benzylamine |
| trans-4-[(2-Amino-3,5-dibrombenzyl)amino]cyclohexanolhydrochlorid |
| NA 872 hydrochloride |
| AMBRIL |
| Ambroxol HCl |
| EINECS 245-899-2 |
| BLUIBRON |
| Ankisol |
| Stas-Hustenloser |
| FRENOPECT |